What question did this study set out to answer?

To assess the impact of crizanlizumab on vaso-occlusive crisis incidence compared to hydroxyurea in sickle cell disease.

December 8, 2025Blood

Increased risk of vaso-occlusive crisis in patients with sickle cell disease treated with crizanlizumab: A real-world analysis using the trinetx database

View Full Paper

Ask AI

Bookmark

Authors

RJReyad Al JabiriLincoln Medical Center RNRama NadaLincoln Medical Center SISura IssaJacobi Medical Center

Discussion

Member takes

Implication

Real-world analysis shows crizanlizumab increases vaso-occlusive crisis rates in sickle cell disease patients compared to hydroxyurea, suggesting a need for reevaluation of treatment strategies.

Key Points

To assess the impact of crizanlizumab on vaso-occlusive crisis incidence compared to hydroxyurea in sickle cell disease.
Retrospective cohort study using the TriNetX database
Inclusion of adults aged ≥18 years with HbSS genotype
Comparison of crizanlizumab and hydroxyurea treatment cohorts
Propensity score matching to balance confounders
Primary outcome measurement of VOC rates at 3 months, 1 year, and 3 years.
202 patients included after matching, 101 in each cohort
Patients treated with crizanlizumab had significantly higher VOC rates at 3 months (RR 1.37), 1 year (RR 1.36), and 3 years (RR 1.12)
Hospitalization rates did not differ significantly between groups at any time point.

Cite This Study

Jabiri et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d021 https://doi.org/10.1182/blood-2025-7967

View Full Paper

Ask AI

Bookmark

Implication

Real-world analysis shows crizanlizumab increases vaso-occlusive crisis rates in sickle cell disease patients compared to hydroxyurea, suggesting a need for reevaluation of treatment strategies.

Increased risk of vaso-occlusive crisis in patients with sickle cell disease treated with crizanlizumab: A real-world analysis using the trinetx database

Discussion

Member takes

Implication

Key Points

Cite This Study

Increased risk of vaso-occlusive crisis in patients with sickle cell disease treated with crizanlizumab: A real-world analysis using the trinetx database

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider